Ergomar Shortage: What Providers and Prescribers Need to Know in 2026

Patients prescribed Ergomar (ergotamine tartrate 2 mg sublingual tablets) for migraine and cluster headache are increasingly presenting to your office, to telehealth encounters, or calling your nurse line with a common complaint: they cannot find their medication at their local pharmacy.

This article provides a concise clinical and logistical overview for neurologists, headache specialists, PCPs, and NPs/PAs who manage patients on Ergomar. It addresses the current availability landscape, clinical considerations when contemplating alternatives, and practical steps you can take to support patients who are struggling to fill their prescriptions.

Current Availability Status of Ergomar (2026)

As of 2026, Ergomar is not listed on the FDA's Drug Shortage Database. There is no systemic manufacturing shortage, no FDA safety recall, and no national distribution failure associated with the product.

The issue is structural: Ergomar is a low-volume, brand-name-only specialty product with a single manufacturer (Pangea Pharmaceuticals). Most retail pharmacies do not stock it as part of their standard formulary. Patients must either seek out pharmacies that carry it, request special orders, or use mail-order pharmacy. This creates a functional access problem that, from the patient's perspective, is clinically indistinguishable from a shortage.

Why This Matters Clinically

Ergomar is not typically a first-line agent—patients on it generally have a specific clinical indication for ergotamine over triptans. These include:

Triptan non-responders or patients with contraindications to triptans

Patients with high migraine recurrence rates who benefit from ergotamine's longer duration of action (lower 24-hour recurrence versus triptans in comparative trials)

Patients with menstrual migraine or prolonged attacks lasting multiple days

Patients who experience significant nausea with oral medications and benefit from the sublingual route, which bypasses gastrointestinal absorption and first-pass hepatic metabolism

Patients with cluster headache for whom ergotamine provides abortive relief

When these patients cannot access Ergomar, they may present to urgent care, the ED, or your office with undertreated attacks. They may also self-escalate to medication overuse of other agents.

Clinical Alternatives When Ergomar Is Unavailable

When counseling patients on temporary alternatives, consider the following, keeping in mind each patient's individual contraindications:

Dihydroergotamine (DHE) nasal spray (Migranal, Trudhesa): Pharmacologically the closest alternative. DHE shares ergotamine's contraindications (pregnancy, peripheral vascular disease, CYP3A4 inhibitors) but has a well-established long duration of action and low headache recurrence profile. Trudhesa's Precision Olfactory Delivery (POD) technology offers improved nasal absorption. Available through most specialty and mail-order pharmacies.

Triptans (sumatriptan, rizatriptan, eletriptan, frovatriptan): Widely available, including inexpensive generics. For patients with high recurrence, frovatriptan or naratriptan (longer half-life, lower recurrence) may be more appropriate. Remind patients to wait at least 24 hours after any ergotamine dose before starting a triptan (72 hours for eletriptan).

CGRP antagonists (ubrogepant/Ubrelvy, rimegepant/Nurtec ODT): For patients with cardiovascular contraindications to both triptans and ergot alkaloids, gepants offer an alternative without vasoconstrictive effects. Rimegepant also has a preventive indication. Note: gepants have their own CYP3A4 interactions to consider.

Key Prescribing and Safety Reminders for Ergomar

Boxed warning. Ergomar carries a boxed warning for serious and/or life-threatening peripheral ischemia when co-administered with potent CYP3A4 inhibitors, including macrolide antibiotics (clarithromycin, erythromycin, troleandomycin) and HIV protease inhibitors (ritonavir, nelfinavir, indinavir, cobicistat). These combinations are contraindicated.

Dosing limits. Maximum 2 tablets per attack; no more than 5 tablets (10 mg) per 7-day period. Chronic daily administration is contraindicated due to risk of ergotism, rebound headache, and dependency.

Pregnancy contraindication. Ergomar is absolutely contraindicated in pregnancy (oxytocic properties) and nursing.

Cardiovascular screening. Screen for coronary artery disease, uncontrolled hypertension, and peripheral vascular disease before prescribing.

Practical Steps to Help Your Patients Access Ergomar

Send prescriptions to specialty or mail-order pharmacies. Route Ergomar prescriptions to specialty pharmacies that routinely handle low-volume brand-name medications. This dramatically improves fill success rates.

Inform patients about the savings program. The Ergomar Savings Program (ergomar.com) allows eligible commercially insured patients to pay as little as $10, with up to $800 savings per month supply. This can make the medication affordable enough to fill at participating pharmacies.

Prescribe a bridge medication. Consider co-prescribing a second migraine abortive (e.g., a triptan, DHE nasal spray) for use when Ergomar is temporarily unavailable. Document the clinical rationale.

Refer patients to medfinder. medfinder for providers helps patients find pharmacies that can fill specialty prescriptions like Ergomar. It calls pharmacies near the patient and texts them the results—reducing patient burden and unnecessary care escalation.

Summary for Prescribers

Ergomar is not in an FDA shortage, but its limited retail availability creates real barriers for patients. Proactive prescribing strategies—routing to specialty pharmacies, co-prescribing backup agents, and connecting patients with the Ergomar Savings Program—can prevent undertreated attacks and unnecessary care escalation. See also: How to Help Your Patients Find Ergomar in Stock: A Provider's Guide.